[{"orgOrder":0,"company":"Anew Medical","sponsor":"Redwoods Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Alpha Klotho-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Anew Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Anew Medical \/ Redwoods Acquisition Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Anew Medical \/ Redwoods Acquisition Corp."},{"orgOrder":0,"company":"Anew Medical","sponsor":"Japan\u2019s Okinawa Research Center","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Klotho Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Anew Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Anew Medical \/ Japan\u2019s Okinawa Research Center","highestDevelopmentStatusID":"4","companyTruncated":"Anew Medical \/ Japan\u2019s Okinawa Research Center"}]

Find Clinical Drug Pipeline Developments & Deals by Anew Medical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The collaboration aims to focus on the research and development of ANEW’s patented Klotho gene therapy in enhancing longevity and reducing age-related diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 27, 2024

                          Lead Product(s) : Klotho Gene Therapy

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Japan’s Okinawa Research Center

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : ANEW intends to use the proceeds from the transaction to progress its lead gene therapy programs including, Alpha Klotho-based gene therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 30, 2023

                          Lead Product(s) : Alpha Klotho-based Gene Therapy

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Redwoods Acquisition Corp.

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank